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Purpose: We undertake a preliminary Monte Carlo study to 
assess the suitability (in terms of radiation dose response) of 
a novel monolithic silicon detectoras a possible array 
detector for use in MRI-linac facilities.  
Methods: The detector, named MagicPlate512 (M512), is a 
thin (470 μm) monolithic silicon with 512 diodes spaced 2 mm 
apart across a maximum detection area of 46 x 46 mm2. The 
array has been designed specifically for small-field 
measurements [1]. Using the GEANT4 toolkit (v9.6.p02), the 
M512’s geometry was simulated at 1.5 cm depth in a 30 x 30 
x 30 cm3 water phantom at 100 cm SSD. Phase space files 
based on the spectrum of a 6MV linac [2] were used as the 
particle source. Field sizes ranging from 0.5 x 0.5 cm2 to 3 x 
3 cm2 were used. Uniform magnetic fields of strength 1 T and 
3 T were applied, in both the in-line and perpendicular 
magnetic-field-to-photon-beam orientations. Simulations 
were run until the average of 100 runs gave 0.5% error along 
the central axis, which generally involved recycling particles 
780 times (approx. 96 CPUh).  
Results: In the in-line orientation, the M512 responds to 
within 3% of the water equivalent response, which is 
comparable to the zero-field case (see Figure 1 parts (a) and 
(b)). In the perpendicular orientation we see an over- and 
under- response in opposing penumbral regions respectively 
(along the Lorentz force vector running from left to right, see 
Figure 1 part (c)). The behavior in penumbral regions is 
similar to that of the silicon array detector previously 
investigated [3] by this group. 
We also observed the consequences of a 2 mm air gap above 
the detector’s sensitive volumes for the perpendicular field 
orientation; it caused a drop in output of (22.0 ± 0.5)% and 
(57.0 ± 0.5)% for 1 T and 3 T field strengths respectively, 
relative to the 0 T case. 
 
 
 
Figure 1: Dose-difference maps of the M512 compared to the 
water-equivalent case, for zero magnetic field (part (a)), a 3 
T in-line magnetic field (part (b)) and a 3 T perpendicular 
magnetic field (part (c)). The dotted line represents the 
photon field edge (1 x 1 cm2). Adjacent pixels are spaced 2 
mm apart. 
 
Conclusions: The M512 is expected to be a valuable tool for 
2D dose-mapping in MRI-linac facilities, especially considering 
its closely pitched diodes for detecting changes to beam 
profiles in a magnetic field. Future work includes 
experimental validation of simulation results using a custom 
designed permanent magnet system. 
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Purpose: Recent advances of immunotherapy make possible 
to combine with radiotherapy. Applying a radiobiological 
model for radiotherapy is one of the methods to optimize 
treatment plans and regimens, biologically. The aim of this 
study was to assess the NTCP model with immunological 
aspects1,2) including stochastic distribution as intercellular 
uncertainties.  
Material/Methods: In the clinical 3D radiotherapy treatment 
planning system (Eclipse ver.11.0, Varian medical systems, 
US), biological parameters3) such as α/β, n, m, TD50 including 
repair parameters (repair half-life) can be set as any given 
values to calculate the NTCP of normal tissues such as the 
rectum and bladder. Using a prostate cancer patient data 
with VMAT commissioned as a 6 MV photon beam of Novalis-
Tx (BrainLab, US) in clinical use, the dose fraction protocols 
in this analysis were set as 70-78Gy/35-39fr, 72-81Gy/40-
45fr, 52.5-66Gy/16-22fr, 35-40Gy/5fr of 5-7 fractions in a 
week. By use of stochastic biological model applying for 
Gaussian distribution, the effects of the NTCP variation of 
repair parameters of the immune system as well as the 
intercellular uncertainty of normal tissues have been 
evaluated. 
Results: As respect to the difference of the α/β, the changes 
of the NTCP between fraction schedules were increased 
especially in hypo-fraction regimens. The difference of the n, 
m affects the variation of the NTCP with the fraction 
schedules, independently.  The elongation of repair half-time 
(long) increased the NTCP twice or much higher in case of 
hypo-fraction scheme. The effects of stochastic distributions 
of the α/β affects the increase of the NTCP, however the 
distributions of the m affects decrease of the NTCP in case of 
hypo-fraction schemes. 
Conclusion: We have shown the variety and difference of the 
α/β, n, m, TD50 including repair parameters (repair half-life) 
of normal tissues compared to default fixed value, which 
have highly affected by probability of cell death and cure. 
Hypo-fractionation schemes seemed to have advantages for 
the variations of the m, while disadvantages for the 
variations of the α/β. The possibility of an increase of the 
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α/β or TD50 in normal tissue by immunological aspects was 
expected to improve normal tissue response in radiotherapy. 
For more precise prediction of such optimal protocols, 
treatment planning systems should be incorporated the 
biological optimization in clinical practice. 
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The Italian Center for Oncologic Hadrontherapy is up to date 
in the fifth year of its clinical activity. The total number of 
patients treated is 685 (up to November 2015). The 
treatments with carbon ions are about three times those with 
protons. An important part of treatments with carbon ions is 
directed on sarcomas, bones and soft tissue sarcomas, 
salivary glands tumours. In the table, treated patients are 
listed according to the clinical trials approved by the Italian 
Ministry of Health.  
Another substantial part of treatments regards re-irradiation 
of several pathologies, especially head and neck re-
treatments of several tumours. 
An important goal reached in the last year is the treatment 
of moving targets. Pancreatic adenocarcinomas, hepatocellar 
carcinomas and pathologies located in moving sites are 
treated through the vertical beam line with gating and 
rescanning technology. 
Treated volumes’ issue has been discussed. Many pelvic 
sarcomas and chordomas cases refer to hadrontherapy 
treatment when already reached remarkable volumes. These 
cases are subject of discussion amongst radiation oncologists 
and medical physicists. The parameters taken in 
consideration are PTV (Planning Treatment Volume) and GTV 
(Gross Tumour Volume). They are statistically evaluated to 
elaborate the best treatment strategy in term of dose and 
planning option. This issue has also economic implications. 
The treatment of major tumour volumes using mostly more 
than one field occupies the treatment room for a period of 
time equal, when not superior, to two or more patients. The 
next challenge is to improve all steps to give such treatments 
in less time. 
Most of the patients treated at CNAO are referred from 
Italian Cancer institutes but an increasing number of EU 
patients comes to Pavia through international agreements. 
In the coming period CNAO is expected to receive the 
authorization to treat all the clinical case worth to receive 
hadrontherapy treatment.  
Clinical study description Particle
Total 
number 
of 
patients 
treated
Proton radiation therapy for chordomas and chondrosarcomas of the 
skull base Protons 52
Proton therapy of spine chordoma and chondrosarcoma (amended) Protons 16
Proton therapy of intracranial meningioma Protons 24
Proton therapy of brain tumors Protons 11
Proton therapy of recurrent cervico-cephalic area tumors Protons 21
Proton boost for locally advanced cervico-cephalic area tumors Protons 28
Proton therapy of glioblastoma Protons 1
Proton re-irradiation of recurrent spine  chordoma and Protons 6
Carbon ion therapy of  adenoid cystic carcinoma of salivary glands Carbon ions 106
Carbon ion re-irradiation of recurrent pleomorphic adenomas Carbon ions 19
Carbon ion re-irradiation of recurrent rectal cancer Carbon ions 8
Carbon ion radiotherapy for bone and soft tissue sarcoma of cervico-
cephalic area Carbon ions 94
Carbon ion radiotherapy for bone and soft tissue sarcoma of trunk Carbon ions 119
Carbon ion  therapy of recurrent cervico-cephalic area tumors Carbon ions 90
Carbon ion therapy of malignant melanoma of the mucous of the 
upper aerodigestive tract Carbon ions 14
Carbon ion therapy for high risk prostate cancer Carbon ions 9
Carbon ion therapy of primary and secondary orbital tumors Carbon ions 13
Carbon ion therapy for pancreatic cancers Carbon ions 11
Carbon ions therapy of primary malignant tumors of the liver Carbon ions 4
Carbon ion re-irradiation of recurrent spinal chordoma and Carbon ions 7
Protons and/or carbon ion integrated radiotherapy for poor prognosis 
in patients with inoperable sinonasal tumor
Protons/ Carbon 
ions 4
Other - 28
685  
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Molecular imaging provides unique information on the tumor 
phenotype (i.e. tumor cells and tumor microenvironment), 
influencing treatment decisions and adaptation of therapy by 
early prediction of treatment outcome. With the increasing 
importance of systemic targeted therapies and of high 
precision external beam radiotherapy, interrogating tumor 
characteristics before and during therapy becomes 
increasingly important. 
Key features like tumor metabolism, proliferation and 
protein synthesis can be depicted by the well-known 
radiopharmaceuticals FDG, FLT and e.g. FAZA, respectively. 
Furthermore, imaging receptor expression on tumor cells 
with e.g. radiolabeled antibodies and peptides can provide 
information on the presence, heterogeneity, accessibility, 
and modulation of these receptors for targeted therapies. 
Thirdly, small molecules like TKI may radiolabeled providing 
similar insight in tumor pathophysiology allowing better 
selection of patients likely to respond to treatment. A 
distinct form of theranostics utilizes targeting molecules, 
radiolabeled with an gamma or positron emission for imaging 
selecting patients for treatment with the same molecule, 
now radiolabeled with a beta-emitter. 
In conclusion, various applications of theranostics provide 
crucial insight in tumor biology, the choice and adaptation of 
treatment, allowing better selection of treatment to achieve 
better outcomes for cancer patients.  
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